ES2138618T3 - Esteroides 17-sustituidos utiles en el tratamiento del cancer. - Google Patents

Esteroides 17-sustituidos utiles en el tratamiento del cancer.

Info

Publication number
ES2138618T3
ES2138618T3 ES93906670T ES93906670T ES2138618T3 ES 2138618 T3 ES2138618 T3 ES 2138618T3 ES 93906670 T ES93906670 T ES 93906670T ES 93906670 T ES93906670 T ES 93906670T ES 2138618 T3 ES2138618 T3 ES 2138618T3
Authority
ES
Spain
Prior art keywords
carbon atoms
beta
hydrogen atom
pyridyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906670T
Other languages
English (en)
Inventor
Susan Elaine Barrie
Michael Jarman
Gerard Andrew Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2138618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929207057A external-priority patent/GB9207057D0/en
Priority claimed from GB929224880A external-priority patent/GB9224880D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2138618T3 publication Critical patent/ES2138618T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA GENERAL (I) EN LA QUE X REPRESENTA EL RESIDUO DE LOS ANILLOS A, B Y C DE UN ESTEROIDE, R REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUILO DE ENTRE 1 Y 4 ATOMOS DE CARBONO, R14 REPRESENTA UN ATOMO DE HIDROGENO Y R15 REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUIL O DE ALCOXIDO DE ENTRE 1 Y 4 ATOMOS DE CARBONO, O UN GRUPO DE HIDROXIDO O DE ALQUILCARBONILOXIDO DE ENTRE 2 Y 5 ATOMOS DE CARBONO O R14 Y R15 JUNTAS REPRESENTAN UN DOBLE ENLACE Y R16 REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUIL DE ENTRE 1 Y 4 ATOMOS DE CARBONO EN FORMA DE BASES LIBRES O DE SALES DE ADICION ACIDA FARMACOLOGICAMENTE ACEPTABLES, CON LA SALVEDAD DE QUE EL 17-(3-PIRIDIL)ANDROSTA-5,14,16TRIEN-3(BETA)-OL Y 15(BETA)-ACETOXI-17-(3-PIRIDIL)ANDROSTA-5,16-DIEN-3(BETA)-OL Y SUS 3-ACETATOS Y EL 3(BETA)-METOXI-17-(3-PIRIDIL)ANDROS-16-ENE SON RECLAMADOS SOLAMENTE PARA SU USO EN LA TERAPIA, LOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEPENDIENTES DE LOS ANDROGENOS, ESPECIALMENTE DEL CANCER PROSTATICO, Y TAMBIEN DE LAS ENFERMEDADES DEPENDIENTES DE LOS ESTROGENOS TALES COMO EL CANCER DE PULMON.
ES93906670T 1992-03-31 1993-03-15 Esteroides 17-sustituidos utiles en el tratamiento del cancer. Expired - Lifetime ES2138618T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207057A GB9207057D0 (en) 1992-03-31 1992-03-31 Steroids
GB929224880A GB9224880D0 (en) 1992-11-27 1992-11-27 Steroids

Publications (1)

Publication Number Publication Date
ES2138618T3 true ES2138618T3 (es) 2000-01-16

Family

ID=26300621

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906670T Expired - Lifetime ES2138618T3 (es) 1992-03-31 1993-03-15 Esteroides 17-sustituidos utiles en el tratamiento del cancer.

Country Status (16)

Country Link
EP (1) EP0633893B1 (es)
JP (1) JP2742331B2 (es)
KR (1) KR100235135B1 (es)
AT (1) ATE186913T1 (es)
AU (1) AU668144B2 (es)
CA (1) CA2132449C (es)
CZ (1) CZ287434B6 (es)
DE (2) DE69327096T2 (es)
DK (1) DK0633893T3 (es)
ES (1) ES2138618T3 (es)
GB (1) GB2265624B (es)
IL (1) IL105078A (es)
LU (1) LU91911I2 (es)
MX (1) MX9301525A (es)
NZ (1) NZ249911A (es)
WO (1) WO1993020097A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721461B1 (en) * 1993-09-30 1999-02-03 Btg International Limited Synthesis of 17-(3-pyridyl) steroids
FI961792A0 (fi) * 1993-10-27 1996-04-26 Merrell Pharma Inc Steroidi-C17-20-lyaasiestäjinä käyttökelpoiset delta16-tyydyttymättömät heterosykliset C17-steroidit
ES2260303T3 (es) 2000-11-17 2006-11-01 Takeda Pharmaceutical Company Limited Derivados de imidazol, metodo para su produccion, y su uso.
WO2002040470A1 (en) 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
JP2005516927A (ja) * 2001-12-13 2005-06-09 アボット・ラボラトリーズ 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
SI1781683T1 (sl) * 2004-08-24 2012-06-29 Btg Int Ltd Postopek za pripravo 17-vinil-triflatov kot intermediatov
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
CN101528309A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 包括给予维生素d化合物和另外的治疗剂的治疗癌症的方法
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
WO2011088160A2 (en) * 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
KR101823275B1 (ko) 2010-08-04 2018-03-08 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
AU2011343637A1 (en) * 2010-12-16 2013-05-30 Biomarin Pharmaceutical Inc. C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
CN102321142A (zh) * 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙晶型及其制备方法
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
RS55223B1 (sr) 2011-10-10 2017-02-28 Zach System Postupak za dobijanje 17-supstituisanih steroida
CN103059090B (zh) * 2011-10-20 2016-06-22 连云港润众制药有限公司 醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
EP2607371A1 (en) 2011-12-23 2013-06-26 Crystal Pharma, S.A.U. Processes for the preparation of abiraterone and related compouds
CN103172690B (zh) * 2011-12-23 2016-08-24 重庆医药工业研究院有限责任公司 醋酸阿比特龙及其中间体的制备方法
CN103193849B (zh) * 2012-01-04 2016-05-04 连云港润众制药有限公司 一种高纯度醋酸阿比特龙的制备方法
CN103254265B (zh) 2012-02-21 2016-07-13 上海希迈医药科技有限公司 醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN102627681B (zh) * 2012-03-23 2016-04-13 山东新时代药业有限公司 一种醋酸阿比特龙的制备方法
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013159225A1 (en) * 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
RU2014154009A (ru) 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
CN102731605B (zh) * 2012-06-19 2016-04-13 鲁南制药集团股份有限公司 一种醋酸阿比特龙的纯化方法
US9512169B2 (en) * 2012-07-10 2016-12-06 Bayer Pharma Aktiengesellschaft 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
WO2014009437A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014016830A1 (en) * 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
ITMI20121788A1 (it) 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
EP2917225A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making abiraterone-3-acetate
EP2917226A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making the 17-triflate intermediate of abiraterone-3-acetate
TWI570131B (zh) * 2012-11-13 2017-02-11 賽克系統公司 製備１７－經取代類固醇之方法
WO2014075978A1 (en) 2012-11-16 2014-05-22 Synthon B.V. Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) * 2012-11-22 2017-04-19 常州靶点医药科技有限公司 一种避免重金属残留的醋酸阿比特龙的制备方法
CN103864878A (zh) * 2012-12-12 2014-06-18 天津大学 阿比特龙醋酸酯的制备方法
WO2014102833A2 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Process for abiraterone acetate
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2968219B1 (en) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
EP2792682B1 (en) 2013-04-19 2016-11-09 Zach System Process for producing a solid form of abiraterone acetate
EP3013844A4 (en) * 2013-06-24 2017-03-01 Sun Pharmaceutical Industries LTD Process for preparation of abiraterone acetate
US9676815B2 (en) 2013-07-29 2017-06-13 Industriale Chimica S.R.L. Process for the preparation of abiraterone or abiraterone acetate
ITMI20131861A1 (it) * 2013-11-08 2015-05-09 Ind Chimica Srl Processo per la preparazione di abiraterone e abiraterone acetato
EP3027638B1 (en) 2013-07-29 2017-12-27 Industriale Chimica S.R.L. Process for the preparation of abiraterone and abiraterone acetate
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN104558091B (zh) * 2013-10-16 2017-07-28 天津金耀集团有限公司 一种醋酸阿比特龙的合成方法
ES2741505T3 (es) 2014-01-28 2020-02-11 Olon Spa Procedimiento para la preparación de acetato de abiraterona y sus productos intermedios
CN103965282B (zh) 2014-04-21 2016-01-20 武汉百科药物开发有限公司 一种醋酸阿比特龙的制备方法
US9315541B2 (en) 2014-05-20 2016-04-19 Olon S.P.A. Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
WO2016001208A1 (en) 2014-06-30 2016-01-07 Galenicum Health S.L. Stable pharmaceutical compositions in the form of immediate release tablets
CZ2014475A3 (cs) 2014-07-09 2016-01-20 Zentiva, K.S. Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku
EP3191087A1 (en) 2014-09-12 2017-07-19 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2016090098A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
ES3019912T3 (en) 2014-12-05 2025-05-21 Aragon Pharmaceuticals Inc Anticancer compositions
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
JP6842474B2 (ja) * 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． ステロイド系化合物、当該化合物を含む組成物及びその使用
TN2018000366A1 (en) 2016-06-03 2020-06-15 Aragon Pharmaceuticals Inc Anticancer compositions.
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
US11865215B2 (en) 2018-04-26 2024-01-09 Synthon B.V. Tablet compositions comprising abiraterone acetate
HU231297B1 (hu) 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用
CA3148115A1 (en) 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer
EP3854384A1 (en) 2020-01-27 2021-07-28 Adamed Pharma S.A. Pharmaceutical formulation comprising abiraterone acetate
UY39201A (es) 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
AU2023214795A1 (en) 2022-02-04 2024-09-19 Janssen Pharmaceutica Nv Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
CN116917306A (zh) * 2022-02-18 2023-10-20 上海醇健医药技术有限公司 17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物
CN116589519A (zh) * 2023-05-17 2023-08-15 江西川奇药业有限公司 一种醋酸阿比特龙及其中间产物的合成方法
CN121443291A (zh) 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224288A (en) * 1987-04-22 1989-12-21 Merrell Dow Pharma 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
ATE186913T1 (de) 1999-12-15
KR100235135B1 (ko) 2000-01-15
AU668144B2 (en) 1996-04-26
EP0633893B1 (en) 1999-11-24
EP0633893A1 (en) 1995-01-18
DK0633893T3 (da) 2000-04-17
NZ249911A (en) 1996-06-25
WO1993020097A1 (en) 1993-10-14
JP2742331B2 (ja) 1998-04-22
CZ287434B6 (en) 2000-11-15
GB9305269D0 (en) 1993-05-05
LU91911I2 (fr) 2012-02-07
MX9301525A (es) 1994-02-28
AU3758493A (en) 1993-11-08
IL105078A0 (en) 1993-07-08
DE69327096D1 (de) 1999-12-30
GB2265624B (en) 1995-04-19
CA2132449C (en) 2002-09-10
IL105078A (en) 1997-11-20
CZ233794A3 (en) 1995-02-15
DE122012000012I1 (de) 2012-06-14
KR950700923A (ko) 1995-02-20
CA2132449A1 (en) 1993-10-14
DE69327096T2 (de) 2000-06-21
GB2265624A (en) 1993-10-06
JPH07505377A (ja) 1995-06-15

Similar Documents

Publication Publication Date Title
ES2138618T3 (es) Esteroides 17-sustituidos utiles en el tratamiento del cancer.
RU2210574C2 (ru) Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
GR3033524T3 (en) Steroids which inhibit angiogenesis.
SE7713341L (sv) Sett att framstella grenade och cykloalifatiska estrar ur androstan- och ostranserierna
PT92168B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de nucleos de estrogenios para provocar a inibicao da actividade de esteroides sexuais
JP2000509388A (ja) 抗炎症薬剤として有用なステロイドナイトレートエステル誘導体を含有する新規医薬組成物
IL87894A0 (en) Androstane 17-carboxylic acid esters,their preparation and pharmaceutical compositions containing them
DE2960689D1 (en) Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application
GB1038333A (en) Pharmaceutical compositions
US3637668A (en) N-substituted 4-aminosteroids
HU176558B (en) Process for preparing new n-enolesters of steroids
ES439957A1 (es) Un procedimiento para la preparacion de d-homoesteroides de la serie del pregnano.
KR940701260A (ko) 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법
GB989881A (en) Improvements in or relating to 10 -methyl steroids and the production thereof
GB905845A (en) Steroid compounds and the preparation thereof
SE332172B (es)
TW343976B (en) 17-substituted steroids useful in cancer treatment
GB1089915A (en) Novel 7-alkyl-19-nor-steroids
GB1063663A (en) Improvements in or relating to steroids and the manufacture thereof
ES403723A2 (es) Un procedimiento para la preparacion de esteroides de la serie del pregnano
GB1074468A (en) Carbalkoxyhtdrazones of the androstane adn estrane series
GB1101120A (en) 2-aminocarbonyl-3-amino-í¸-steroids
GR22382B (el) Βελτιωσεις εις η σχετικως προς μεθοδους παρασκευης νεων στεροειδων ενωσεων.
GB1113184A (en) The manufacture of 10ª‡-steroids
WO1990015067A3 (fr) NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633893

Country of ref document: ES